RxDoctor Payments Data

Kavani Milani, MD

Family Medicine · Fairfax, VANPI 1104919570

Payments from drug & device makers

$15,208in general payments, 2019–2025

Across 692 payments — averaging $21.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Novo Nordisk$2K
  • Merz North America, Inc.$2K
  • Lilly USA, LLC$1K
  • Pfizer$995
  • AstraZeneca$968
  • plus $4K from 48 others

What the payments were for

  • Food & beverage$15,140100%
  • Education$550%
  • Entertainment$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,208 in reported general payments places this provider in the 95th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$97,911
Medicare patients
257
Services billed
1,133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide78$103,483
JardianceEmpagliflozin73$80,510
TrulicityDulaglutide43$53,514
FarxigaDapagliflozin Propanediol47$50,283
LinzessLinaclotide15$15,689
MounjaroTirzepatide11$10,964
Celecoxib60$2,235
Venlafaxine Hcl ErVenlafaxine Hcl22$1,534
Tolterodine Tartrate ErTolterodine Tartrate13$1,355
Rosuvastatin Calcium78$1,276
Tamsulosin Hcl76$1,064
Pantoprazole Sodium45$1,026
Levothyroxine Sodium96$884
Metformin Hcl177$872
Atorvastatin Calcium118$869

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,061$103,48378 claims
Boehringer IngelheimJardiance$342$80,51073 claims
Lilly USA, LLCTrulicity, Mounjaro$1,342$64,47854 claims
AstraZenecaFarxiga$968$50,28347 claims
AbbVieLinzess$3,631$15,68915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →